AstraZeneca total voting rights 1,550,712,906 as of Oct 31, 2025

AstraZeneca PLC reported its total voting rights under the UK Disclosure and Transparency Rule 5.6.1.

Rhea-AI Filing Summary

AstraZeneca PLC reported its total voting rights under the UK Disclosure and Transparency Rule 5.6.1. As at 31 October 2025, the company’s issued share capital with voting rights comprised 1,550,712,906 ordinary shares of US$0.25. No shares are held in Treasury, so the total number of voting rights is 1,550,712,906.

This figure serves as the denominator shareholders use to assess whether they must notify their interest or any change in interest in line with UK transparency rules. The company files annual reports on Form 20-F and indicated it is not furnishing information under Rule 12g3-2(b).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What total voting rights did AstraZeneca (AZN) report?

As at 31 October 2025, AstraZeneca reported 1,550,712,906 total voting rights, representing ordinary shares of US$0.25 each.

Does AstraZeneca (AZN) hold any treasury shares?

No. The company reported that no shares are held in Treasury.

How should AZN shareholders use the reported voting rights figure?

Shareholders may use 1,550,712,906 as the denominator to determine if they must notify holdings under UK transparency rules.

Which annual report form does AstraZeneca (AZN) use?

AstraZeneca files annual reports on Form 20-F.

Is AstraZeneca furnishing information under Rule 12g3-2(b)?

No. The company indicated it is not furnishing information under Rule 12g3-2(b).

What is the par value of AstraZeneca’s ordinary shares?

Ordinary shares have a par value of US$0.25 each.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 01:22 PM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights

3 November 2025

Transparency Directive

Voting rights and capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 October 2025 the issued share capital of AstraZeneca PLC with voting rights is 1,550,712,906 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,712,906.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 03 November 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary